Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach.

A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/